Trial reportBritish journal of clinical pharmacology2006
A double-blind, placebo-controlled investigation of the residual psychomotor and cognitive effects of zolpidem-MR in healthy elderly volunteers.
Trial report in British journal of clinical pharmacology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs.Drugs & aging · 2012Pooled it
- Effect of a sleep aid in analgesia after arthroscopic rotator cuff repair.Yonsei medical journal · 2015Trial
- The use of a non-benzodiazepine hypnotic sleep-aid (Zolpidem) in patients undergoing ACL reconstruction: a randomized controlled clinical trial.Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA · 2011Trial
- Trial
- Effect of lemborexant on insomnia severity, morning alertness, and cognition in participants with insomnia disorder and mild obstructive sleep apnea.Sleep medicine: X · 2026Article
- The interaction between orexin, sleep deprivation and Alzheimer's disease: Unveiling an Emerging Connection.The journal of physiological sciences : JPS · 2025Review
- Effect of a dual orexin receptor antagonist on Alzheimer's disease: Sleep disorders and cognition.Frontiers in medicine · 2022Review
- Association Between the Use of Non-benzodiazepine Hypnotics and Cognitive Outcomes: A Systematic Review.Current sleep medicine reports · 2020Article
- Mild cognitive impairment: associations with sleep disturbance, apolipoprotein e4, and sleep medications.Sleep medicine · 2018Article
- Inhibition of Orexin Signaling Promotes Sleep Yet Preserves Salient Arousability in Monkeys.Sleep · 2016Article
- Sleep, cognition, and normal aging: integrating a half century of multidisciplinary research.Perspectives on psychological science : a journal of the Association for Psychological Science · 2015Review
- Discovery and development of orexin receptor antagonists as therapeutics for insomnia.British journal of pharmacology · 2014Review
- Quantitative electroencephalography within sleep/wake states differentiates GABAA modulators eszopiclone and zolpidem from dual orexin receptor antagonists in rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2013Article
- Dual orexin receptor antagonists show distinct effects on locomotor performance, ethanol interaction and sleep architecture relative to gamma-aminobutyric acid-A receptor modulators.Frontiers in neuroscience · 2013Article
- Insomnia and chronic heart failure.Heart failure reviews · 2009Review
- Insomnia in patients with depression: some pathophysiological and treatment considerations.CNS drugs · 2009Review
- Comparative tolerability of newer agents for insomnia.Drug safety · 2009Review
- Sleep and Its Disorders in Seniors.Sleep medicine clinics · 2008Article
- Insomnia: zolpidem extended-release for the treatment of sleep induction and sleep maintenance symptoms.MedGenMed : Medscape general medicine · 2007Review
- Update on the safety considerations in the management of insomnia with hypnotics: incorporating modified-release formulations into primary care.Primary care companion to the Journal of clinical psychiatry · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo assess residual psychomotor and cognitive effects of a modified-release formulation of zolpidem (zolpidem-MR), developed to provide sustained hypnotic efficacy during the whole night, compared with placebo and flurazepam.
methodsTwenty-four healthy elderly volunteers received four study treatments (zolpidem-MR 6.25 mg and 12.5 mg, placebo and flurazepam 30 mg) using a randomized, cross-over, double-blind design. Residual psychomotor and cognitive effects were assessed with a psychometric test battery. Quality of sleep and residual effects were evaluated subjectively with the Leeds Sleep Evaluation Questionnaire.
resultsPsychometric performance was significantly impaired with flurazepam but not with zolpidem-MR at either dose. Ease of falling asleep and sleep quality were significantly improved with both doses of zolpidem-MR and with flurazepam. Neither active drug modified perception of well-being on awakening.
conclusionIn elderly subjects, zolpidem-MR showed no residual functional impairment in psychometric or cognitive tests sensitive to flurazepam.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.